Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Indena Publishes Six Studies in 2009
November 25, 2009
2 Min Read
MILAN, ItalyIndena had six studies published this year on the efficacy of its extracts, including:
A study Phytomedicine showing Silymarin BIO-C® significantly increased circulating prolactin levels.
A double blind clinical trial published in Alternative Medicine Review found GreenSelect® Phytosome® produced more significant weight loss and decreased body mass index in the 50 volunteers under the controlled diet and taking the product compared to the control group subjects under the control diet.
A molecular docking study conducted published in Journal of Enzyme Inhibition and Medicinal Chemistry investigated the role of Green Tea catechins in chemoprevention of cancer. The docking experiments showed catechins and the examined drugs compete for the same catalytic binding site, using a comparable binding mode.
A seven arms animal study reported in Alternative Medicine Review suggested the Ginkgo biloba Ginkgoselect® Phytosome® has significant cardiac protection and antioxidant activities while the combination with Ocimum sanctum leaf extract did not show better activity than Ginkgoselect Phytosome alone.
A study published in Phytotherapy Research found Indenas CPV extract ( Crataegus oxyacantha, Passiflora incarnata and Valeriana officinalis) presented no toxicity in vivo, suggesting this association may have similar lack of toxicity in human beings.
A study on gene expression showed Mirtoselect® anthocyanins can attenuate the expression level of pro-inflammatory genes and restore anti-inflammatory genes in an inflammatory cell model, providing a rationale for the anti-inflammatory activity of bilberry anthocyanins.
New C-seco-taxoids synthesized from 10-deacetylbaccatin III and their potencies have been evaluated against drug-sensitive and drug-resistant cancer cell lines, in addition to molecular modeling studies, including molecular dynamics simulations, on the drug-protein complexes of class I and III beta-tubulins were performed to identify possible cause of the remarkable potency of these C-seco-taxoids against paclitaxel-resistant cell lines overexpressing class III beta-tubulin.
You May Also Like